Objectives: To evaluate the safety and effectiveness of once-daily gastroretentive gabapentin (G-GR) for treatment of PHN in real-world clinical practice. Methods: Patients aged ≥18 years were divided into 2 cohorts: patients ≤70 years and patients >70 years.